LIMK2 and osteosarcoma: Regarding the management of osteosarcoma, preclinical studies have shown that apatinib promotes apoptosis and autophagy through VEGFR2/STAT3/BCL-2 signaling pathways in osteosarcoma cells, as well as attenuates invasion and migration through RhoA/ROCK/LIMK2 pathways (12, 13).